Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.

ABSTRACT:

Background

Molecular characterization of breast cancer allows subtype-directed interventions. Estrogen receptor (ER) is the longest-established molecular marker.

Methods

We used six established population models with ER-specific input parameters on age-specific incidence, disease natural history, mammography characteristics, and treatment effects to quantify the impact of screening and adjuvant therapy on age-adjusted US breast cancer mortality by ER status from 1975 to 2000. Outcomes included stage-shifts and absolute and relative reductions in mortality; sensitivity analyses evaluated the impact of varying screening frequency or accuracy.

Results

In the year 2000, actual screening and adjuvant treatment reduced breast cancer mortality by a median of 17 per 100000 wo

SUBMITTER: Munoz D 

PROVIDER: S-EPMC4271026 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature